Skip Ribbon Commands
Skip to main content
Sign In

26018 Next-Gen Sequencing, Hematologic Neoplasms (NGSHM)

Next-Gen Sequencing, Hematologic Neoplasms (NGSHM)
Test Code: NGSHMSO
Test Components
​This test includes next-generation sequencing to evaluate for the following 35 genes and intronic regions: ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PHF6, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.
Useful For

Evaluation of hematologic neoplasms at the time of diagnosis, to assist in appropriate classification and prognosis. 

Determine the presence of new clinically important gene mutation changes at relapse.

Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Bone Marrow (preferred) ​EDTA Lavender Top Tube (LTT) or ACD (YTT) ​Heparin Green Top Tube (GTT) ​2 mL ​1 mL
​Blood ​EDTA Lavender Top Tube (LTT) or ACD (YTT) ​Heparin Green Top Tube (GTT) ​3 mL ​1 mL
Collection Processing Instructions
1. Invert several times to mix bone marrow.
2. Send specimen in original tube.
3. Label specimen as bone marrow.
 
The following information is required:
1. Clinical Diagnosis
2. Pertinent clinical history
3. Clinical or morphologic suspicion
4. Date of collection
5. Specimen source
Specimen Stability Information
Specimen Type Temperature Time
​Bone Marrow ​ ​Ambient (preferred) ​14 days
​Refrigerate ​14 days
​Blood ​ Ambient (preferred) ​14 days
​Refrigerate ​14 days
Rejection Criteria
Gross Hemolysis
​Bone marrow biopsies, slides, paraffin shavings or frozen tissues and paraffin-embedded tissues, paraffin-embedded bone marrow aspirates, or moderately to severely clotted
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories ​Monday, Wednesday, Friday ​14-21 days ​Somatic Mutation Detection by Next-Generation Sequencing (NGS)
Reference Lab
Reference Range Information
Interpretive Report
Interpretation
​Mutations (gene alterations) identified, if present. An interpretive report will be provided.
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​81450
Test Components
​This test includes next-generation sequencing to evaluate for the following 35 genes and intronic regions: ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PHF6, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.
Ordering Applications
Ordering Application Description
​COM Next-Gen Sequencing, Hematologic Neoplasms (NGSHM)
​Centricity Next-Gen Sequencing, Hematologic Neoplasms (NGSHM)
​Cerner Next-Gen Sequencing, Hematologic Neoplasms (NGSHM)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Bone Marrow (preferred) ​EDTA Lavender Top Tube (LTT) or ACD (YTT) ​Heparin Green Top Tube (GTT) ​2 mL ​1 mL
​Blood ​EDTA Lavender Top Tube (LTT) or ACD (YTT) ​Heparin Green Top Tube (GTT) ​3 mL ​1 mL
Collection Processing
1. Invert several times to mix bone marrow.
2. Send specimen in original tube.
3. Label specimen as bone marrow.
 
The following information is required:
1. Clinical Diagnosis
2. Pertinent clinical history
3. Clinical or morphologic suspicion
4. Date of collection
5. Specimen source
Specimen Stability Information
Specimen Type Temperature Time
​Bone Marrow ​ ​Ambient (preferred) ​14 days
​Refrigerate ​14 days
​Blood ​ Ambient (preferred) ​14 days
​Refrigerate ​14 days
Rejection Criteria
Gross Hemolysis
​Bone marrow biopsies, slides, paraffin shavings or frozen tissues and paraffin-embedded tissues, paraffin-embedded bone marrow aspirates, or moderately to severely clotted
Useful For

Evaluation of hematologic neoplasms at the time of diagnosis, to assist in appropriate classification and prognosis. 

Determine the presence of new clinically important gene mutation changes at relapse.

Test Components
​This test includes next-generation sequencing to evaluate for the following 35 genes and intronic regions: ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PHF6, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.
Reference Range Information
Interpretive Report
Interpretation
​Mutations (gene alterations) identified, if present. An interpretive report will be provided.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories ​Monday, Wednesday, Friday ​14-21 days ​Somatic Mutation Detection by Next-Generation Sequencing (NGS)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​81450
For most current information refer to the Marshfield Laboratory online reference manual.